Investors

Key press releases

28 Sep 2022
16:25 E.S.T.

Cellectis Appoints Mark Frattini, M.D., Ph.D. as Chief Medical Officer

01 Sep 2022
16:30 E.S.T.

Cellectis Announces Participation in Four Upcoming Investor Conferences in September

04 Aug 2022
16:30 E.S.T.

Cellectis Provides Business Update and Reports Financial Results for Second Quarter 2022

Key upcoming events

28 Sep 2022 ‐ 29 Sep 2022

Jefferies Cell and Genetic Medicine Summit

Learn more

Key corporate presentation

Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on the Euronext Growth Paris (ticker: ALCLS).

$2.4300

+0.0500 (2.1008%)

Prev. close: 2.3800
Volume: 314,141
High: 2.5000
Capitalization: 110.591M

€2.4580

-0.0920 (-3.6078%)

Prev. close: 2.5500
Volume: 17,671
High: 2.6000
Capitalization: 111.778M

See stock information

Covering research analysts

Barclays - Gena Wang

Citi - Yigal Nochomovitz

Goldman Sachs - Salveen Richter

Jefferies - Kelly Shi

JMP Securities - Silvan Tuerkcan

Jones Trading - Soumit Roy

Kempen - Ingrid Gafanhão

Oddo BHF - Martial Descoutures

Oppenheimer – Hartaj Singh

RW Baird - Jack Allen

Wells Fargo – Nick Abbott

William Blair – Raju Prasad

SMBC - David Dai

Cellectis contact information

Arthur Stril, Chief Business Officer

Ashley R. Robinson, LifeSci Advisors

investors@cellectis.com

Citibank ADR contact information

Intermediaries & Investors
US: +1 212 723 5435
UK: +44 207 500 2030

citiadr@citi.com

Société Générale Securities Services - Ordinary Shares contact information

Call center in English and French

Monday to Friday from 8:30am to 6pm CEST

+33 (0)2 51 85 67 89